Translational Development Acquisition Corp. (TDACW) Stock Price & Analysis
Translational Development Acquisition Corp. (TDACW) fell 8.39% to USD 1.42 as of June 10, 2026 at 03:48 UTC, according to Nexqual real-time market data.
TDACW last closed at USD 1.55; the session ranged USD 1.35–1.55 on volume of 60,922 shares. Market capitalization is —, with a 52-week range of USD 1.35–1.55 (NGM). Source: Nexqual, June 10, 2026 at 03:48 UTC.
Key Statistics (as of June 10, 2026 at 03:48 UTC)
| Price | USD 1.42 |
|---|---|
| Change | ▼ 8.39% (down) |
| Previous Close | USD 1.55 |
| Open | USD 0.33 |
| Day Range | USD 1.35 – 1.55 |
| 52-Week Range | USD 1.35 – 1.55 |
| Volume | 60,922 shares |
| Market Cap | — |
| Exchange | NGM |
Technical Analysis (TDACW)
Nexqual's technical model rates TDACW "BUY" based on 5 bullish and 3 bearish signals across 66 daily candles, as of June 10, 2026 at 03:48 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 100 (overbought) |
| vs SMA50 | Above (USD 0.21) |
| MACD | 0.1 (positive) |
Analyst Ratings (TDACW)
Wall Street analysts rate TDACW "None", per Nexqual as of June 10, 2026 at 03:48 UTC.
| Consensus Rating | None |
|---|
Earnings (TDACW)
Source: Nexqual, June 10, 2026 at 03:48 UTC.
Financials & Fundamentals (TDACW)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| Current Ratio | 0.09 |
| Total Cash | $24,630 |
| Total Debt | $500,000 |
| Free Cash Flow | $-352,611 |
Source: Nexqual, June 10, 2026 at 03:48 UTC.
Financial Health Score (TDACW)
Nexqual rates Translational Development Acquisition Corp.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 03:48 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Gross margin 0%, operating 0% |
| Balance Sheet | Mixed — $25K cash, no debt |
| Cash Flow | Weak — Operating cash flow -$682K |
| Efficiency | Mixed — No data |
Ownership (TDACW)
| Shares Outstanding | 13.88M |
|---|---|
| Float | 13.54M |
Source: Nexqual, June 10, 2026 at 03:48 UTC.
Leadership (TDACW)
Translational Development Acquisition Corp. is led by Michael M. B. Hoffman (age 75), Chairman of the Board & CEO, per Nexqual as of June 10, 2026 at 03:48 UTC.
| Chairman of the Board & CEO | Michael M. B. Hoffman (age 75) |
|---|---|
| Chief Financial Officer | Avi C. Das |
Major Backers & Investors (TDACW)
Notable institutional backers of Translational Development Acquisition Corp. include Magnetar Financial LLC, Shaolin Capital Management LLC, CSS LLC, according to Nexqual as of June 10, 2026 at 03:48 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Magnetar Financial LLC | 7.54% |
| Shaolin Capital Management LLC | 7.44% |
| CSS LLC | 6.75% |
| AQR Arbitrage LLC | 6.35% |
| Healthcare of Ontario Pension Plan Trust Fund | 5.22% |
| Verition Fund Management, LLC | 5.19% |
| Polar Asset Management Partners Inc. | 4.64% |
| LMR Partners LLP | 4.64% |
Source: Nexqual, June 10, 2026 at 03:48 UTC.
From Translational Development Acquisition Corp.'s Latest SEC 10-K Filing (filed 2026-03-30)
Key Strengths & Strategy (as disclosed to the SEC)
- Translational Development Acquisition Corp. does not have significant operations.
- The company intends to effect a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| TDAC | Translational Development Acqui | USD 10.72 | ▼ 0.19% |
| APXTW | Apex Treasury Corporation Warrants | USD 0.28 | ▲ 10% |
| TDACU | Translational Development Acqui | USD 12.7 | ▲ 13.9% |
| SVACW | Starboard Value Acquisition Cor | USD 1.6 | ▲ 18.52% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 03:48 UTC. This page is informational and not investment advice.